Orlistat in the treatment of overweight or obese Chinese patients with newly diagnosed Type 2 diabetes

Diabetic Medicine

Volumn 22, Issue 12, 2005, Pages 1737-1743

  Shi, Yi Fan ^a   Pan, C Y ^b   Hill, J ^c   Gao, Y ^d  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^b CHINESE PLA GENERAL HOSPITAL   (China)

^c Roche Products Pty Ltd   (Australia)

^d PEKING UNIVERSITY FIRST HOSPITAL   (China)

Author keywords

Cardiovascular risk factors; Chinese; Newly diagnosed Type 2 diabetes; Obesity; Orlistat

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; PLACEBO; TETRAHYDROLIPSTATIN;

ADULT; AGED; ARTICLE; BODY MASS; CALORIC INTAKE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES CONTROL; DIABETIC OBESITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; HUMAN; IMPAIRED GLUCOSE TOLERANCE; LOW CALORY DIET; LOW FAT DIET; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; RANDOMIZED CONTROLLED TRIAL; WAIST CIRCUMFERENCE; WEIGHT REDUCTION;

ADOLESCENT; ADULT; AGED; ANTI-OBESITY AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DIET, REDUCING; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; LACTONES; MALE; MIDDLE AGED; OBESITY; PROSPECTIVE STUDIES; WEIGHT LOSS;

EID: 30044445497     PISSN: 07423071     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2005.01723.x     Document Type: Article

References (28)

1. Hubert H, Feinleib M, McNamara PM, Castelli WP. Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study. Circulation 1983; 67: 968-977.
2. Lean ME, Han TS, Seidell JC. Impairment of health and quality of life in people with large waist circumference. Lancet 1998; 351: 853-856.
3. Must A, Spadano J, Coakley EH, Field AE, Colditz G, Dietz WH. The disease burden associated with overweight and obesity. J Am Med Assoc 1999; 282: 1523-1529.
4. Hu FB, Manson JE, Stampfer MJ, Colditz G, Liu S, Solomon CG et al. Diet, lifestyle, and the risk of type 2 diabetes mellitus in women. N Engl J Med 2001; 345: 790-797.
5. Fuller JH. Mortality trends and causes of death in diabetic patients. Diabetes Metab 1993; 19: 96-99.
6. Goldstein DJ. Beneficial health effects of modest weight loss. Int J Obes Relat Metab Disord 1992; 16: 397-415.
7. Van Gaal LF, Wauters MA, de Leeuw IH. The beneficial effects of modest weight loss on cardiovascular risk factors. Int J Obes Relat Metab Disord 1997; 21: S5-9.
8. Expert Panel on the Identification, Evaluation, and Treatment of Overweight in Adults. Clinical guidelines on the identification, evaluation and treatment of overweight and obesity in adults: executive summary. Am J Clin Nutr 1998; 68: 899-917.
9. Guerciolini R. Mode of action of orlistat. Int J Obes Relat Metab Disord 1997; 21: S12-23.
10. Zhi J, Melia AT, Guerciolini R, Chung J, Kinberg J, Hauptman JB et al. Retrospective population-based analysis of the dose-response (fecal fat excretion) relationship of orlistat in normal and obese volunteers. Clin Pharmacol Ther 1994; 56: 82-85.
11. Hollander PA, Elbein SC, Hirsch IB, Kelley D, McGill J, Taylor T et al. Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study. Diabetes Care 1998; 21: 1288-1294.
12. Hanefeld M, Sachse G. The effects of orlistat on body weight and glycaemic control in overweight patients with type 2 diabetes: a randomized, placebo-controlled trial. Diabetes Obes Metab 2002; 4: 415-423.
13. Miles JM, Leiter L, Hollander P, Wadden T, Anderson JW, Doyle M et al. Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin. Diabetes Care 2002; 25: 1123-1128.
14. Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004; 27: 155-161.
15. Kelley DE, Bray GA, Pi-Sunyer FX, Klein S, Hill J, Miles J et al. Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: a 1-year randomized controlled trial. Diabetes Care 2002; 25: 1033-1041.
16. Wing RR, Koeske R, Epstein LH, Nowalk MP, Gooding W, Becker D. Long-term effects of modest weight loss in type II diabetic patients. Arch Intern Med 1987; 147: 1749-1753.
17. Kelley DE, Kuller LH, McKolanis TM, Harper P, Mancino J, Kalhan S. Effects of moderate weight loss and orlistat on insulin resistance, regional adiposity, and fatty acids in type 2 diabetes. Diabetes Care 2004; 27: 33-40.
18. Pi-Sunyer FX. A review of long-term studies evaluating the efficacy of weight loss in ameliorating disorders associated with obesity. Clin Ther 1996; 18: 1006-1035.
19. Meigs JB, Singer DE, Sullivan LM, Dukes KA, D'Agostino RB, Nathan DM et al. Metabolic control and prevalent cardiovascular disease in non-insulin-dependent diabetes mellitus (NIDDM): the NIDDM Patient Outcome Research Team. Am J Med 1997; 102: 38-47.
20. Rossner S, Sjostrom L, Noack R, Meinders AE, Noseda G. Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years' treatment with orlistat for obesity. Obes Res 2000; 8: 49-61.
21. Broom I, Wilding J, Stott P, Myers N, UK Multimorbidity Study Group. Randomized trial of the effect of orlistat on body weight and cardiovascular disease risk profile in obese patients: UK Multimorbidity Study. Int J Clin Pract 2002; 56: 494-499.
22. Davidson MH, Hauptman J, DiGirolamo M, Foreyt JP, Halsted CH, Heber D et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. J Am Med Assoc 1999; 281: 235-242.
23. Wing RR, Marcus MD, Epstein LH, Salata R. Type II diabetic subjects lose less weight than their overweight non-diabetic spouses. Diabetes Care 1987; 10: 563-566.
24. Fuchtenbusch M, Standl E, Schatz H. Clinical efficacy of new thiazolidinediones and glinides in the treatment of type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes 2000; 108: 151-163.
25. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-865.
26. Erratum in Lancet 352: 1557.
27. Rosenfalck AM, Hendel H, Rasmussen MH, Almdal T, Anderson T, Hilsted J et al. Minor long-term changes in weight have beneficial effects on insulin sensitivity and β-cell function in obese subjects. Diabetes Obes Metab 2002; 4: 19-28.
28. Damci T, Yalin S, Balci H, Osar Z, Korugan U, Ozyazar M et al. Orlistat augments postprandial increases in glucagon-like peptide 1 in obese type 2 diabetic patients. Diabetes Care 2004; 27: 1077-1080.